•• Complete epithelial recovery was achieved by 67% of subjects receiving NEXAGON, as opposed to 27% receiving Vehicle alone
•• NEXAGON was well-tolerated demonstrating a safety profile similar to vehicle
•• Amber plans to initiate the NEXPEDE-1 Phase 2/3 clinical trial in subjects with PCED of various etiologies in Q1 2023 ••
International Stem Cell Corporation announced that the United States Patent and Trademark Office has granted ISCO a patent relating to the company's development of human non-embryonic parthenogenetic stem cells. Human parthenogenetic stem cells are
Read More